



## Cancer Control Program Community Oncology Committee

200 First Street, SW  
Rochester, MN 55905  
P: 507-266-9202  
F: 507-284-1803

[www.allianceforclinicaltrialsinoncology.org](http://www.allianceforclinicaltrialsinoncology.org)

Robert J. Behrens, M.D.  
Walter R. Peters, Jr., M.D.  
Jon Strasser, M.D.  
Co-Chairs

### Agenda Community Oncology Committee Meeting Saturday, November 8, 2014 10:00 AM – 1:00 PM CDT Room: Avedon C

**Meeting available by teleconference: Dial 800-501-8979 Access Code: 2107872**

Committee Leadership Members:		
Robert J. Behrens, MD	Co-chair	<a href="mailto:rbehrens@cancercenterofiowa.com">rbehrens@cancercenterofiowa.com</a>
Walter R. Peters, Jr., MD	Co-chair	<a href="mailto:wpeters@columbiasurgical.com">wpeters@columbiasurgical.com</a>
Jon Strasser, MD	Co-chair	<a href="mailto:jstrasser@christianacare.org">jstrasser@christianacare.org</a>
Jan C. Buckner, MD	CCP Program Director	<a href="mailto:buckner.jan@mayo.edu">buckner.jan@mayo.edu</a>
Jacqueline M. Lafky, MS	CCP Program Manager	<a href="mailto:lafky.jacqueline@mayo.edu">lafky.jacqueline@mayo.edu</a>
Guests:		
Monica Bertagnolli, MD	Axel Grothey, MD	Vicky Seewaldt, MD
Lyudmila Bazhenova, MD	Worta McCaskill-Stevens, MD	Nancy You, MD
Paul Brown, MD	Rudy Navari, MD, PhD	
George Chang, MD	Kathryn Ruddy, MD	

#### I. Administrative Updates

New Pathology Representative: Dr. Neil Abrahams

#### II. (10:30) ACS CRP Education Committee (5 minutes)

*Nancy You, MD*

#### III. Protocol Presentations (15 minutes each)

- A. A211102: Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1,1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women  
*PI: Vicky Seewaldt, MD; [victoria.seewaldt@duke.edu](mailto:victoria.seewaldt@duke.edu)*
- B. A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma  
*Co-PIs: Alyx Porter Umphrey, MD; [Porter.alyx@mayo.edu](mailto:Porter.alyx@mayo.edu) and Sadhna Kohli, PhD, MPH; [Kohli.sadhna@mayo.edu](mailto:Kohli.sadhna@mayo.edu)  
Presenter: Paul Brown, MD; [pdbrown@mdanderson.org](mailto:pdbrown@mdanderson.org)*
- C. A221301: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial  
*PI: Rudy Navari, MD, PhD; [rmnavari@gmail.com](mailto:rmnavari@gmail.com)*
- D. S1400 (Lung-MAP): Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer  
*Alliance PI: Everett Vokes, MD; [evokes@medicine.bsd.uchicago.edu](mailto:evokes@medicine.bsd.uchicago.edu)  
Presenter: Lyudmila Bazhenova, MD; [lbazhenova@ucsd.edu](mailto:lbazhenova@ucsd.edu)*

- E. A221303: Randomized Study of Early Palliative Care Integrated with Standard Oncology Care Versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies  
*PI: Jennifer Temel, MD; [jtemel@partners.org](mailto:jtemel@partners.org)*  
*Presenter: Katie Ruddy, MD; [Ruddy.Kathryn@mayo.edu](mailto:Ruddy.Kathryn@mayo.edu)*

**IV. NCORP Transition** (20 minutes each)

- A. NCORP Transition Overview  
*Robert Behrens, MD*
- B. Alliance Membership for Community Sites  
*Trini Ajazi*
- C. CCDR Update  
*George Chang, MD*
- D. Open Forum  
*Worta McCaskill-Stevens, MD will be available for Q&A*

**V. Alliance Foundation and ACCRU** (20 minutes)  
*Monica Bertagnolli, MD and Axel Grothey, MD*

**VI. Other Business**